Year: 2004 Source: 2p. SIEC No: 20040604

This article reports on a recent request by the US Food & Drug Administration (FDA) that manufacturers of several antidepressant drugs (including Prozac, Zoloft, & Paxil) include in their labeling a warning statement that recommends close observation of patients for worsening depression or the emergence of suicidality. The clinical findings that contributed to the advisory are reviewed & the need for more careful monitoring of patients receiving antidepressant treatment is emphasized.